Thrombosis Research

Article	Citations
Incidence of thrombotic complications in critically ill ICU patients with COVID-19	3229
Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy	1538
Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis	1205
The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management	424
Severe COVID-19 infection associated with endothelial activation	335
Thrombosis risk associated with COVID-19 infection. A scoping review	283
Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels	275
Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID)	187
The clinical implication of dynamic neutrophil to lymphocyte ratio and D-dimer in COVID-19: A retrospective study in Suzhou China	179
Venous thromboembolism in patients with COVID-19: Systematic review and meta-analysis	168
D-dimer level is associated with the severity of COVID-19	144
Pulmonary embolism in patients with COVID-19: Time to change the paradigm of computed tomography	143
Clinical and computed tomography characteristics of COVID-19 associated acute pulmonary embolism: A different phenotype of thrombotic disease?	137
Thrombotic complications of patients admitted to intensive care with COVID-19 at a teaching hospital in the United Kingdom	135
Mechanisms involved in the development of thrombocytopenia in patients with COVID-19	116
Severe arterial thrombosis associated with Covid-19 infection	113
Is COVID-19 associated thrombosis caused by overactivation of the complement cascade? A literature review	104
Anticoagulation and bleeding risk in patients with COVID-19	92
Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism	91
Image-proven thromboembolism in patients with severe COVID-19 in a tertiary critical care unit in the United Kingdom	91
Estrogen and thrombosis: A bench to bedside review	88
Admission D-dimer levels, D-dimer trends, and outcomes in COVID-19	79
Incidence of thrombotic complications and overall survival in hospitalized patients with COVID-19 in the second and first wave	76
Pulmonary embolism in hospitalised patients with COVID-19	73
The role of Neutrophil Extracellular Traps in Covid-19: Only an hypothesis or a potential new field of research?	72

Spontaneous HIT syndrome: Knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia	71
Pulmonary embolism in COVID-19 patients: prevalence, predictors and clinical outcome	70
Mechanisms of thrombosis and cardiovascular complications in COVID-19	69
COVID-19 and cardiovascular consequences: Is the endothelial dysfunction the hardest challenge?	68
Incidence of venous and arterial thromboembolic complications in COVID-19: A systematic review and meta-analysis	68
ADAMTS13 activity, von Willebrand factor, factor VIII and D-dimers in COVID-19 inpatients	64
Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?	62
Venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review	55
A relative ADAMTS13 deficiency supports the presence of a secondary microangiopathy in COVID 19	55
Venous thromboembolism in non-critically ill patients with COVID-19 infection	55
COVID-19 and thrombotic microangiopathies	52
Biomarkers for the prediction of venous thromboembolism in critically ill COVID-19 patients	50
Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination	48
Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: Prospective results from a multi-center study	47
Sustained inflammation, coagulation activation and elevated endothelin-1 levels without macrovascular dysfunction at 3 months after COVID-19	46
Pulmonary embolism in a young pregnant woman with COVID-19	44
Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies	43
Measuring functional limitations after venous thromboembolism: Optimization of the Post-VTE Functional Status (PVFS) Scale	43
Prevalence and characteristics of pulmonary embolism in 1042 COVID-19 patients with respiratory symptoms: A nested case-control study	43
Drug-drug interactions with direct oral anticoagulants associated with adverse events in the real world: A systematic review	43
D-dimer cut-off points and risk of venous thromboembolism in adult hospitalized patients with COVID-19	43
Covid-19 associated autoimmune thrombotic thrombocytopenic purpura: Report of a case	42
Incidence and impact of disseminated intravascular coagulation in COVID-19 a systematic review and meta-analysis	41
In vitro hemocompatibility testing of medical devices	41
Genetically predicted obesity and risk of deep vein thrombosis	40
Thrombotic antiphospholipid syndrome: A practical guide to diagnosis and management	39
The gut microbiome and thromboembolism	39
Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19	38
Incidence and mortality due to thromboembolic events during the COVID-19 pandemic: Multi-sourced population-based health records cohort study	38
The effect of anticoagulation on clinical outcomes in novel Coronavirus (COVID-19) pneumonia in a U.S. cohort	37
Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action	36
Intensity of anticoagulation and survival in patients hospitalized with COVID-19 pneumonia	36
Cerebral venous thrombosis and thrombocytopenia post-COVID-19 vaccination	36
Prothrombotic disturbances of hemostasis of patients with severe COVID-19: A prospective longitudinal observational study	35
Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study	35
COVID-19 versus HIT hypercoagulability	35
Impact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: A longitudinal controlled before-after study	34
Incidence of venous thromboembolic events in COVID-19 patients after hospital discharge: A systematic review and meta-analysis	34
Pulmonary infarction in acute pulmonary embolism	33
Lemierre syndrome: Current evidence and rationale of the Bacteria-Associated Thrombosis, Thrombophlebitis and LEmierre syndrome (BATTLE) registry	33
Targeting raised von Willebrand factor levels and macrophage activation in severe COVID-19: Consider low volume plasma exchange and low dose steroid	32
Higher procoagulatory potential but lower DIC score in COVID-19 ARDS patients compared to non-COVID-19 ARDS patients	31
Portal vein thrombosis in a patient with COVID-19	31
Current imaging modalities for diagnosing cerebral vein thrombosis – A critical review	30
Thrombotic risk in children with COVID-19 infection: A systematic review of the literature	29
COVID-19 associated coagulopathy: Thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy	29
Arterial and venous thromboembolic disease in a patient with COVID-19: A case report	29
Pulmonary embolism: A complication of COVID 19 infection	28
Endothelial function improvement in patients with familial hypercholesterolemia receiving PCSK-9 inhibitors on top of maximally tolerated lipid lowering therapy	28
Intestinal microbiota dysbiosis play a role in pathogenesis of patients with primary immune thrombocytopenia	28

Systemic thrombosis in a large cohort of COVID-19 patients despite thromboprophylaxis: A retrospective study	28
Relationship between body mass index, risk of venous thromboembolism and pulmonary embolism: A systematic review and dose-response meta-analysis of cohort studies among four million participants	28
Incidence of thrombotic outcomes for patients hospitalized and discharged after COVID-19 infection	27
Advances in the management of coagulopathy in acute promyelocytic leukemia	27
Risk prediction for cancer-associated thrombosis in ambulatory patients with cancer: past, present and future	26
COVID-19 and thrombosis: The role of hemodynamics	26
ADAMTS 13 deficiency is associated with abnormal distribution of von Willebrand factor multimers in patients with COVID-19	26
Is bivalirudin an alternative anticoagulant for extracorporeal membrane oxygenation (ECMO) patients? A systematic review and meta-analysis	25
Translational insight into prothrombotic state and hypercoagulation in nonalcoholic fatty liver disease	25
Catheter-directed thrombolysis in COVID-19 pneumonia with acute PE: Thinking beyond the guidelines	25
Phosphatidylserine-exposing blood cells, microparticles and neutrophil extracellular traps increase procoagulant activity in patients with pancreatic cancer	24
Prediction models for recurrence and bleeding in patients with venous thromboembolism: A systematic review and critical appraisal	24
A comprehensive assessment of the coagulation profile in critically ill COVID-19 patients	24
Apixaban and rivaroxaban anti-Xa level utilization and associated bleeding events within an academic health system	24
Efficacy and safety of a 12-week outpatient pulmonary rehabilitation program in Post-PE Syndrome	24
The antithrombotic effect of caffeic acid is associated with a cAMP-dependent pathway and clot retraction in human platelets	24
Perioperative management of a severe congenital hypofibrinogenemia with thrombotic phenotype	24
Anti Xa activity after high dose LMWH thrombosis prophylaxis in covid 19 patients at the intensive care unit	23
Novel contributions of neutrophils in the pathogenesis of abdominal aortic aneurysm, the role of neutrophil extracellular traps: A systematic review	23
The use of prophylaxis in the treatment of rare bleeding disorders	23
Timing of venous thromboembolism diagnosis in hospitalized and non-hospitalized patients with COVID-19	23
Absence of hypercoagulability after nCoV-19 vaccination: An observational pilot study	22
The significance of disseminated intravascular coagulation on multiple organ dysfunction during the early stage of acute respiratory distress syndrome	22
Bacterial outer membrane vesicles induce disseminated intravascular coagulation through the caspase-11-gasdermin D pathway	22
COVID-19 and thrombotic complications: Pulmonary thrombosis rather than embolism?	22
Venous thromboembolism and coronavirus disease 2019 in an ambulatory care setting - A report of 4 cases	22
Management of venous thromboembolism in pregnancy	22
Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE	22
Links between thrombosis and inflammation in traumatic brain injury	22
Thrombotic thrombocytopenic purpura (TTP) after COVID-19 vaccination: A systematic review of reported cases	21
ROTEM diagnostic capacity for measuring fibrinolysis in neonatal sepsis	21
Blocking podoplanin inhibits platelet activation and decreases cancer-associated venous thrombosis	21
A perfect storm: Root cause analysis of supra-therapeutic anticoagulation with vitamin K antagonists during the COVID-19 pandemic	21
Antiphospholipid syndrome and antiphospholipid antibody profile in patients with retinal vein occlusion	21
Age-adjusted D-dimer cut-off levels to rule out venous thromboembolism in COVID-19 patients	21
Arterial and venous thrombosis: What's the link? A narrative review	21
Clinical practice guidelines for the treatment and prevention of cancer-associated thrombosis	21
A perioperative bivalirudin anticoagulation protocol for neonates with congenital diaphragmatic hernia on extracorporeal membrane oxygenation	21
Venous thromboembolic events in the setting of extracorporeal membrane oxygenation support in adults: A systematic review	21
Heavy menstrual bleeding in women on oral anticoagulants	21
Utility of the platelet function analyser (PFA-100/200) for exclusion or detection of von Willebrand disease: A study 22 years in the making	20
Role of upfront CT pulmonary angiography at admission in COVID-19 patients	20
Rotational thromboelastometry to assess hypercoagulability in COVID-19 patients	20
Recombinant human DNase I for the treatment of cancer-associated thrombosis: A pre-clinical study	20
The domino effect triggered by the tethered ligand of the protease activated receptors	20
Predictive value of D-dimer testing for the diagnosis of venous thrombosis in unusual locations: A systematic review	20
Deep venous thrombosis in a non-critically ill patient with novel COVID-19 infection	20
Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection	20
The thrombin–inflammation axis in cancer progression	19
COVID-19 and hypercoagulability in the outpatient setting	19
Four cases of acquired hemophilia A following immunization with mRNA BNT162b2 SARS-CoV-2 vaccine	19
Pulmonary embolism and deep vein thrombosis: Similar but different	19
Unusual simultaneous cerebral infarcts in multiple arterial territories in a COVID-19 patient	19
The increased risk of bleeding due to drug-drug interactions in patients administered direct oral anticoagulants	19
Determinants of plasma fibrin clot lysis measured using three different assays in healthy subjects	19
A single center retrospective cohort study evaluating use of direct oral anticoagulants (DOACs) in morbidly obese veteran population	19
Using oral anticoagulants among chronic kidney disease patients to prevent recurrent venous thromboembolism: A systematic review and meta-analysis	19
Three-month follow-up of pulmonary embolism in patients with COVID-19	18
Interference of DOAC stop and DOAC remove in the thrombin generation assay and coagulation assays	18
Testosterone replacement therapy and the risk of venous thromboembolism: A systematic review and meta-analysis of randomized controlled trials	18
Utility of D-dimers and intermediate-dose prophylaxis for venous thromboembolism in critically ill patients with COVID-19	18
Platelet-leukocyte crosstalk in COVID-19: How might the reciprocal links between thrombotic events and inflammatory state affect treatment strategies and disease prognosis?	17
Diverse thrombus composition in thrombectomy stroke patients with longer time to recanalization	17
Direct-acting oral anticoagulants use prior to COVID-19 diagnosis and associations with 30-day clinical outcomes	17
Oral contraceptives and hormone replacement therapy: How strong a risk factor for venous thromboembolism?	17
Twice- or Once-Daily Dosing of Direct Oral Anticoagulants, a systematic review and meta-analysis	17
Patient characteristics and long–term outcomes beyond the first 6 months after a diagnosis of cancer-associated venous thromboembolism	17
Tissue factor in COVID-19-associated coagulopathy	17
Extended half-life recombinant products in haemophilia clinical practice – Expectations, opportunities and challenges	17
Risk of post-thrombotic syndrome after deep vein thrombosis treated with rivaroxaban versus vitamin-K antagonists: A systematic review and meta-analysis	17
Deaths related to pulmonary embolism and cardiovascular events before and during the 2020 COVID-19 pandemic: An epidemiological analysis of data from an Italian high-risk area	16
Incidence of thromboembolic events following administration of four-factor prothrombin complex concentrate (4F-PCC) for oral anticoagulation reversal	16
Low molecular weight heparin and 28-day mortality among patients with coronavirus disease 2019: A cohort study in the early epidemic era	16
Rise of levels of von Willebrand factor and factor VIII with age: Role of genetic and acquired risk factors	16
How we make an accurate diagnosis of von Willebrand disease	16
Management of high-risk pulmonary embolism in pregnancy	16
Prevalence of aPhosphatidylserine/prothrombin antibodies and association with antiphospholipid antibody profiles in patients with antiphospholipid syndrome: A systematic review and meta-analysis	16
Direct oral anticoagulants or low-molecular-weight heparins for venous thromboembolism in patients with brain tumors	16
Extracellular vesicles in atrial fibrillation and stroke	16
D-dimer as a stand-alone test to rule out deep vein thrombosis	16

The pathogenesis of thromboembolic disease in covid-19 patients: Could be a catastrophic antiphospholipid syndrome?	16
Long-term follow-up after successful treatment of vaccine-induced prothrombotic immune thrombocytopenia	16
How I treat von Willebrand disease	15
Extended thromboprophylaxis following major abdominal/pelvic cancer-related surgery: A systematic review and meta-analysis of the literature	15
The impact of hydroxychloroquine on obstetric outcomes in refractory obstetric antiphospholipid syndrome	15
Asymptomatic deep vein thrombosis in critically ill COVID-19 patients despite therapeutic levels of anti-Xa activity	15
Apixaban and rivaroxaban in obese patients treated for venous thromboembolism: Drug levels and clinical outcomes	15
High plasma levels of soluble P-Selectin and Factor VIII predict venous thromboembolism in non-small cell lung cancer patients: The Thrombo-Nsclc risk score	15
Deep vein thrombosis in SARS-CoV-2 pneumonia-affected patients within standard care units: Exploring a submerged portion of the iceberg	15
Direct oral anticoagulant versus low-molecular-weight heparin for treatment of venous thromboembolism in cancer patients: An updated meta-analysis of randomized controlled trials	15
Administrative codes inaccurately identify recurrent venous thromboembolism: The CVRN VTE study	15
Reduced intracellular antioxidant capacity in platelets contributes to primary immune thrombocytopenia via ROS-NLRP3-caspase-1 pathway	15
COVID-19 associated pulmonary thrombosis	15
Suggestions for global coagulation assays for the assessment of COVID-19 associated hypercoagulability	15
An overview of thrombotic complications of old and new anticancer drugs	15
Venous thromboembolism following 672,495 primary total shoulder and elbow replacements: Meta-analyses of incidence, temporal trends and potential risk factors	15
A nomogram model to predict the venous thromboembolism risk after surgery in patients with gynecological tumors	15
Hemostatic biomarkers in occult cancer and cancer risk prediction	15
Translating the success of prophylaxis in haemophilia to von Willebrand disease	15
Preoperative and intraoperative predictors of deep venous thrombosis in adult patients undergoing craniotomy for brain tumors: A Chinese single-center, retrospective study	15
Venous thromboembolism incidence and risk factors in non-small cell lung cancer patients receiving first-line systemic therapy	14
Risk of symptomatic venous thromboembolism in mild and moderate COVID-19: A comparison of two prospective European cohorts	14
Venous thromboembolism in Asia and worldwide: Emerging insights from GARFIELD-VTE	14
Development and prospective validation of a novel risk score for predicting the risk of lower extremity deep vein thrombosis among multiple trauma patients	14
Validation of the PLASMIC score for predicting ADAMTS13 activity <10% in patients with suspected thrombotic thrombocytopenic purpura in Alberta, Canada	14
Coagulation signaling and cancer immunotherapy	14
Pharmacokinetics for haemophilia treaters: Meaning of PK parameters, interpretation pitfalls, and use in the clinic	14
Lifestyle factors and venous thromboembolism in two cohort studies	14
Where do we stand with antithrombotic prophylaxis in patients with COVID-19?	14
Genetic and epigenetic regulation of cancer coagulome – lessons from heterogeneity of cancer cell populations	14
Low admission protein C levels are a risk factor for disease worsening and mortality in hospitalized patients with COVID-19	14
Real-time detection and differentiation of direct oral anticoagulants (rivaroxaban and dabigatran) using modified thromboelastometric reagents	14
Selatogrel, a reversible P2Y12 receptor antagonist, has reduced off-target interference with haemostatic factors in a mouse thrombosis model	14
Time from suspected thrombotic thrombocytopenic purpura to initiation of plasma exchange and impact on survival: A 10-year provincial retrospective cohort study	14
The hazard of fondaparinux in non-critically ill patients with COVID-19: Retrospective controlled study versus enoxaparin	14
Thrombosis in hematological malignancies: mechanisms and implications	14
The prevalence of pulmonary embolism in patients with COVID-19 and respiratory decline: A three-setting comparison	13
Current estimates of the incidence of acute venous thromboembolic disease in Canada: A meta-analysis	13
Effects of platelet and phospholipids on clot formation activated by a small amount of tissue factor	13
ADAMTS13 activity, high VWF and FVIII levels in the pathogenesis of deep vein thrombosis	13
Prediction of hypofibrinogenemia and thrombocytopenia at the point of care with the Quantra® QPlus® System	13
Increased levels of platelet-derived microparticles in pulmonary hypertension	13
COVID-19 risk perceptions, worries and preventive behaviors in patients with previous pulmonary embolism	13
Risk of VTE associated with PORTs and PICCs in cancer patients: A systematic review and meta-analysis	13
Prothrombotic abnormalities in patients with multiple myeloma and monoclonal gammopathy of undetermined significance	13
Extensive pulmonary perfusion defects compatible with microthrombosis and thromboembolic disease in severe Covid-19 pneumonia	13
Overview of risk assessment models for venous thromboembolism in ambulatory patients with cancer	13
Coagulation parameters and venous thromboembolism in patients with and without COVID-19 admitted to the Emergency Department for acute respiratory insufficiency	13
Nephrotic syndrome disease activity is proportional to its associated hypercoagulopathy	13
COVID-19 coagulopathy and thrombosis: Analysis of hospital protocols in response to the rapidly evolving pandemic	13
Association between neutrophil extracellular traps (NETs) and thrombosis in antiphospholipid syndrome	13
Immature platelets: a review of the available evidence	13
Short-term exposure to PM2.5 and risk of venous thromboembolism: A case-crossover study	13
Patients experience of living with cancer associated thrombosis in France (Le PELICAN)	13
Predictors of residual pulmonary vascular obstruction after pulmonary embolism: Results from a prospective cohort study	13
Incidence and prevalence of venous thromboembolism in Norway 2010–2017	13
“Whole life changed” - Experiences of how symptoms derived from acute pulmonary embolism affects life. A qualitative interview study	12
Pulmonary embolism in coronavirus disease-19 (COVID-19) and use of compression ultrasonography in its optimal management	12
Coagulation factors XI and XII as possible targets for anticoagulant therapy	12
COVID-19 adenovirus vaccine triggers antibodies against PF4 complexes to activate complement and platelets	12
Influence of sex on development of thrombosis in patients with COVID-19: From the CLOT-COVID study	12
The neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predict left ventricular thrombus resolution in acute myocardial infarction without percutaneous coronary intervention	12
Frequency and incidence of arterial events in patients with venous thromboembolism compared to the general population: A systematic review and meta-analysis of cohort studies	12
Venous and arterial thromboembolism in patients with cancer treated with targeted anti-cancer therapies	12
Markers of NET formation and stroke risk in patients with atrial fibrillation: association with a prothrombotic state	12
Pharmacokinetics of enoxaparin in COVID-19 critically ill patients	12
Brain-derived extracellular vesicles mediated coagulopathy, inflammation and apoptosis after sepsis	12
Developing and validating natural language processing algorithms for radiology reports compared to ICD-10 codes for identifying venous thromboembolism in hospitalized medical patients	12
Letter to the Editors-in-Chief in response to the article of Abou-Ismail, et al. entitled “Estrogen and thrombosis: A bench to bedside review” (Thrombosis Research 192 (2020) 40–51)	12
Management and outcomes of cancer patients with venous thromboembolism presenting with thrombocytopenia	12
Occurrence of pulmonary embolism in a patient with mild clinical expression of COVID-19	12
Knockdown of liver-derived factor XII by GalNAc-siRNA ALN-F12 prevents thrombosis in mice without impacting hemostatic function	12
A comparison of natural language processing to ICD-10 codes for identification and characterization of pulmonary embolism	12
The incidence of thrombotic events with idarucizumab and andexanet alfa: A systematic review and meta-analysis	11
One-year incidence of venous thromboembolism, bleeding, and death in patients with solid tumors newly initiating cancer treatment: Results from the Cancer-VTE Registry	11
Tissue plasminogen activator for the treatment of adults with critical COVID-19: A pilot randomized clinical trial	11
Anticoagulation in COVID-19 patients – An updated systematic review and meta-analysis	11
Longitudinal multiparametric characterization of platelet dysfunction in COVID-19: Effects of disease severity, anticoagulation therapy and inflammatory status	11
Neutrophil extracellular traps and cancer-associated thrombosis	11
Impact of a commercially available DOAC absorbent on two integrated procedures for lupus anticoagulant detection	11
Efficacy and safety of apixaban for primary prevention in gastrointestinal cancers: A post-hoc analysis of the AVERT trial	11
Antithrombin deficiency: A pediatric disorder	11
Comparison of clinical outcomes using activated partial thromboplastin time versus antifactor-Xa for monitoring therapeutic unfractionated heparin: A systematic review and meta-analysis	11
Genetic and molecular evidence for complement dysregulation in patients with HELLP syndrome	11
Real-world experience with reversal of dabigatran by idarucizumab	11
Adherence to and persistence with direct oral anticoagulant therapy among patients with new onset venous thromboembolism receiving extended anticoagulant therapy and followed by a centralized anticoag	11
Pulmonary embolism: Age specific temporal trends in incidence and mortality in Denmark 1999–2018	11
Persistent circulating platelet and endothelial derived microparticle signature may explain on-going pro-thrombogenicity after acute coronary syndrome	11
Association between Covid-19 and Pulmonary Embolism (AC-19-PE study)	11
Anticoagulation in COVID-19: Randomized trials should set the balance between excitement and evidence	11
Heparin-induced thrombocytopenia: Diagnostic challenges in intensive care patients especially with extracorporeal circulation	11
Antisense oligonucleotides and nucleic acids generate hypersensitive platelets	11
Cancer-associated non-bacterial thrombotic endocarditis	11
Multiparameter microfluidics assay of thrombus formation reveals increased sensitivity to contraction and antiplatelet agents at physiological temperature	11
NLRP3 inflammasome contributes to endotoxin-induced coagulation	11